Balint syndrome in anti-NMDA receptor encephalitis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 2, 2018
- Accepted in final form November 8, 2018
- First Published December 13, 2018.
Author Disclosures
- Aude Metzger, MD, PhD,
- Laure Pisella, PhD,
- Alain Vighetto, MD, PhD,
- Bastien Joubert, MD,
- Jérôme Honnorat, MD, PhD,
- Caroline Tilikete, MD, PhD and
- Virginie Desestret, MD, PhD
- Aude Metzger, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laure Pisella, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alain Vighetto, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bastien Joubert, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jérôme Honnorat, MD, PhD,
Scientific advisory board for Bristol Meyers Squibb
NONE
NONE
NONE
receives royalties from licensing fees to AthenaDiagnostics, Euroimmun, and ravo Diagnostika for a patentfor the use of CV2/CRMP5 as diagnostic tests.
NONE
NONE
NONE
NONE
NONE
NONE
Research support from CSL Behring France
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Caroline Tilikete, MD, PhD and
NONE
NONE
Santhera, funding for travel Teva, funding for travel Novartis, funding for travel and speaker honoraria
Journal of Neuro-Ophthalmology, editorial board member Frontiers in neurology, neuro-ophthalmology, editorial board member
NONE
Neuro-ophtalmologie, Elsevier Masson, 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Virginie Desestret, MD, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Service de neuro-ophtalmologie et neuro-cognition (A.M., A.V., C.T., V.D.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; IMPACT—Integrative, Multisensory (L.P., A.V., C.T.), Perception, Action and Cognition Team, Centre de recherche des Neurosciences de Lyon (CRNL); Université Claude Bernard Lyon 1 (A.V., B.J., J.H., C.T., V.D.); Centre de référence français des syndromes paranéoplasiques (B.J., J.H.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; and Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310 (B.J., J.H., V.D.), équipe synaptopathies et anticorps (SYNATAC), Lyon, France.
- Correspondence
Dr. Metzger aude.metzger{at}chu-lyon.fr
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Special Article
NMDA receptor encephalitis and other antibody-mediated disorders of the synapseThe 2016 Cotzias LectureJosep Dalmau et al.Neurology, December 05, 2016 -
Article
Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodiesEugenia Martinez-Hernandez, Mar Guasp, Anna García-Serra et al.Neurology, March 11, 2020 -
Article
Decreased occipital lobe metabolism by FDG-PET/CTAn anti–NMDA receptor encephalitis biomarkerJohn C. Probasco, Lilja Solnes, Abhinav Nalluri et al.Neurology: Neuroimmunology & Neuroinflammation, November 15, 2017 -
Article
Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitisFranziska Scheibe, Harald Prüss, Annerose M. Mengel et al.Neurology, December 21, 2016